(2R)-2,3-dibenzoyloxybutanedioic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2R)-2,3-dibenzoyloxybutanedioic acid
• 化学式: C₁₈H₁₄O₈
• 分子量: 358.304
• InChiKey: YONLFQNRGZXBBF-KWCCSABGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  26
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  127
• 氢给体数：
  2
• 氢受体数：
  8

文献信息

• PRODRUGS OF OPIOIDS AND USES THEREOF
  申请人：Franklin Richard

  公开号：US20110190267A1

  公开（公告）日：2011-08-04

  The present invention concerns prodrugs of opioid analgesics and pharmaceutical compositions containing such prodrugs. Methods for providing more consistent pain relief by increasing the bioavailability of the opioid analgesic with the aforementioned prodrugs are provided. The invention also provides for decreasing the adverse GI side effects of opioid analgesics.

  本发明涉及阿片类镇痛药的前药以及含有此类前药的药物组合物。本发明提供了通过前述前药增加阿片类镇痛药的生物利用度，从而提供更一致的疼痛缓解方法。该发明还提供了减少阿片类镇痛药对胃肠道的副作用的方法。
• CONJUGATES AND ASSOCIATED METHODS OF PRODUCING THEM FOR THE PREVENTION OR TREATMENT OF NICOTINE ADDICTION
  申请人：Pfizer Inc.

  公开号：US20150329520A1

  公开（公告）日：2015-11-19

  The present invention relates in part to chemical compounds, and methods for producing these compounds. The compounds may also be incorporated into compositions to enhance quit rates or reduce relapse in smoking cessation and further in treating nicotine-related dependence.

  本发明部分涉及化合物和生产这些化合物的方法。这些化合物也可以被纳入组合物中，以增强戒烟成功率或减少复吸，并进一步用于治疗与尼古丁相关的依赖。
• Substituted 1-Benzyl-4-Substituted Piperazine Analogues
  申请人：Hutchison J. Alan

  公开号：US20070249616A1

  公开（公告）日：2007-10-25

  Compounds of Formula I are provided, in which variables are as described herein: Such compounds may be used to modulate MCH binding to MCH receptors in vivo or in vitro, and are particularly useful in the treatment of a variety of metabolic, feeding and sexual disorders in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for treating such disorders are provided, as are methods for using such ligands for detecting MCH receptors (e.g., receptor localization studies).

  提供了公式I的化合物，其中变量如此描述：这些化合物可以用于调节MCH与体内或体外的MCH受体结合，并且在治疗人类、家养伴侣动物和家畜动物的各种代谢、饮食和性功能障碍方面特别有用。提供了用于治疗这些疾病的制药组合物和方法，以及用于检测MCH受体（例如受体定位研究）的配体的方法。
• CHEMICAL COMPOUNDS
  申请人：Di Fabio Romano

  公开号：US20080114049A1

  公开（公告）日：2008-05-15

  The present invention relates to (1S,6R)-6-(3,4-dichlorophenyl)-1-[(methyloxy)methyl]-3-azabicyclo[4.1.0]heptane, pharmaceutically acceptable salts, prodrugs or solvates thereof; processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as serotonin (5-HT), dopamine (DA) and norepinephrine (NE), re-uptake inhibitors.

  本发明涉及(1S,6R)-6-(3,4-二氯苯基)-1-[(甲氧基)甲基]-3-氮杂双环[4.1.0]庚烷，其药学上可接受的盐、前药或溶剂化物；用于其制备的中间体，含有它们的制药组合物以及它们在治疗中的应用，作为5-羟色胺(5-HT)、多巴胺(DA)和去甲肾上腺素(NE)的再摄取抑制剂。
• AZABICYCLIC COMPOUNDS AS INHIBITORS OF MONOAMINES REUPTAKE
  申请人：Bertani Barbara

  公开号：US20100035914A1

  公开（公告）日：2010-02-11

  The present invention relates to novel compounds of formula (I)′, and pharmaceutically acceptable salts, prodrugs or solvates thereof: wherein R 1 is hydrogen or C 1-4 alkyl; R 2 is a group A, K or W wherein A is K is an α or β naphthyl group, optionally substituted by 1 or 2 groups R 18 , each of them being the same or different; and W is and wherein G is a 5,6-membered monocyclic heteroaryl group, or a 8- to 11-membered heteroaryl bicyclic group; wherein G may be substituted by (R 15 ) p , which can be the same or different; p is an integer from 0 to 5; R 3 is selected from the group consisting of: hydrogen, fluorine, and C 1-4 alkyl; or corresponds to a group X or X 1 ; R 4 is selected from the group consisting of: hydrogen, fluorine, and C 1-4 alkyl; or corresponds to a group X or X 1 ; R 5 is hydrogen or C 1-4 alkyl; R 7 is hydrogen or C 1-4 alkyl; or is a group X, X 1 , X 2 or X 3 ; wherein X is X 1 is X 2 is and X 3 is R 6 is hydrogen or C 1-4 alkyl; or is a group X or X 1 ; R 9 is C 1-4 alkyl; R 10 is selected from the group consisting of: hydrogen, halogen, hydroxy, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl and SF 5 ; or corresponds to a group R 8 ; R 8 is a 5-6 membered heterocycle group, which may be substituted by one or two substituents selected from the group consisting of: halogen, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy and C 1-4 alkanoyl; R 11 is selected from the group consisting of: hydrogen, halogen, hydroxy, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl and SF 5 ; or corresponds to a group R 8 ; R 12 is selected from the group consisting of: hydrogen, halogen, hydroxy, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl and SF 5 ; or corresponds to a group R 8 ; R 13 is selected from the group consisting of: hydrogen, halogen, hydroxy, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl and SF 5 ; or corresponds to a group R 8 ; R 14 is selected from the group consisting of: hydrogen, halogen, hydroxy, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl and SF 5 ; or corresponds to a group R 8 ; R 15 is selected from the group consisting of: halogen, hydroxy, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl and SF 5 ; or corresponds to a group R 8 ; R 16 is hydrogen, C 1-4 alkyl, C 3-6 cycloalkyl or C 3-6 cycloalkylC 1-3 alkyl; R 17 is hydrogen or C 1-4 alkyl; R 18 is selected from the group consisting of: halogen, cyano, and C 1-4 alkyl; R 19 is haloC 1-2 alkyl; and n is 1 or 2; with the proviso that: if R 2 is A, R 3 , R 4 , R 5 , R 6 , R 7 , R 10 , R 11 , R 13 , and R 14 are hydrogen, and R 12 is fluorine, R 1 is C 1-4 alkyl; if R 2 is A, R 3 , R 4 , R 5 , R 6 , R 7 , R 10 , R 11 , R 13 , and R 14 are hydrogen, and R 1 is methyl, R 12 is halogen, hydroxy, cyano, C 1-4 alkyl, haloC 1-4 alkyl, C 1-4 alkoxy, haloC 1-4 alkoxy, C 1-4 alkanoyl or SF 5 ; or corresponds to a group R 8 ; and processes for their preparation, intermediates used in these processes, pharmaceutical compositions containing them and their use in therapy, as serotonin (5-HT), dopamine (DA) and norepinephrine (NE), re-uptake inhibitors.

  本发明涉及式(I)'的新化合物，以及其药学上可接受的盐、前药或溶剂化物： 其中， R1为氢或C1-4烷基； R2为A、K或W基团，其中 A为 K为α或β萘基团，可选地被1或2个R18基团取代，每个基团相同或不同； W为 其中， G为5,6-成员单环杂芳基团或8-至11-成员杂芳双环基团；其中G可能被(R15)p取代，其中p可以是0到5的整数；R3选择自氢、氟和C1-4烷基；或对应于X或X1基团； R4选择自氢、氟和C1-4烷基；或对应于X或X1基团； R5为氢或C1-4烷基； R7为氢或C1-4烷基；或为X、X1、X2或X3基团； 其中， X为 X1为 X2为 且X3为 R6为氢或C1-4烷基；或为X或X1基团； R9为C1-4烷基； R10选择自氢、卤素、羟基、氰基、C1-4烷基、卤代C1-4烷基、C1-4烷氧基、卤代C1-4烷氧基、C1-4酰基和SF5；或对应于R8基团； R8为5-6成员杂环基团，可以被来自卤素、氰基、C1-4烷基、卤代C1-4烷基、C1-4烷氧基和C1-4酰基的一或两个取代基团取代； R11选择自氢、卤素、羟基、氰基、C1-4烷基、卤代C1-4烷基、C1-4烷氧基、卤代C1-4烷氧基、C1-4酰基和SF5；或对应于R8基团； R12选择自氢、卤素、羟基、氰基、C1-4烷基、卤代C1-4烷基、C1-4烷氧基、卤代C1-4烷氧基、C1-4酰基和SF5；或对应于R8基团； R13选择自氢、卤素、羟基、氰基、C1-4烷基、卤代C1-4烷基、C1-4烷氧基、卤代C1-4烷氧基、C1-4酰基和SF5；或对应于R8基团； R14选择自氢、卤素、羟基、氰基、C1-4烷基、卤代C1-4烷基、C1-4烷氧基、卤代C1-4烷氧基、C1-4酰基和SF5；或对应于R8基团； R15选择自卤素、羟基、氰基、C1-4烷基、卤代C1-4烷基、C1-4烷氧基、卤代C1-4烷氧基、C1-4酰基和SF5；或对应于R8基团； R16为氢、C1-4烷基、C3-6环烷基或C3-6环烷基C1-3烷基； R17为氢或C1-4烷基； R18选择自卤素、氰基和C1-4烷基； R19为卤代C1-2烷基；且 n为1或2； 但前提是，如果R2为A，R3、R4、R5、R6、R7、R10、R11、R13和R14为氢，而R12为氟，R1为C1-4烷基；如果R2为A，R3、R4、R5、R6、R7、R10、R11、R13和R14为氢，而R1为甲基，R12为卤素、羟基、氰基、C1-4烷基、卤代C1-4烷基、C1-4烷氧基、卤代C1-4烷氧基、C1-4酰基或SF5；或对应于R8基团；以及用于制备它们的过程、用于这些过程的中间体、含有它们的制药组合物以及它们在治疗中的应用，作为5-羟色胺（5-HT）、多巴胺（DA）和去甲肾上腺素（NE）的再摄取抑制剂。